Provided by Tiger Trade Technology Pte. Ltd.

Guardant Health Inc.

170.69
+2.811.67%
Post-market: 170.65-0.0400-0.02%19:30 EDT
Volume:1.92M
Turnover:324.20M
Market Cap:22.91B
PE:-48.72
High:170.85
Open:167.25
Low:165.01
Close:167.88
52wk High:176.58
52wk Low:53.40
Shares:134.20M
Float Shares:129.78M
Volume Ratio:0.71
T/O Rate:1.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5037
EPS(LYR):-3.3203
ROE:-4584.47%
ROA:-18.07%
PB:-102.78
PE(LYR):-51.41

Loading ...

BofA Securities Adjusts Price Target on Guardant Health to $190 From $135

MT Newswires Live
·
Jul 06

Guardant Health is Maintained at Buy by B of a Securities

Dow Jones
·
Jul 06

Guardant Health price target raised to $190 from $135 at BofA

TIPRANKS
·
Jul 06

Guardant Health (GH) Is Up 12.6% After India Shield Cancer Test Deal And UnitedHealth Coverage Expansion

Simply Wall St.
·
Jul 05

Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT) and Guardant Health (GH)

TIPRANKS
·
Jul 03

Zydus Lifesciences Signs Mou with Apollo Hospitals

Reuters
·
Jul 03

Guardant Health: Buy Rating Reaffirmed as UnitedHealth Coverage Expands Shield Access; 12-Month Price Target Maintained at $165

TIPRANKS
·
Jul 02

Guardant news ‘meaningful positive’ but impact modest, says TD

TIPRANKS
·
Jul 02

When Multi-cancer Blood Screens Could Finally Take Off

Dow Jones
·
Jul 02

Unitedhealth Group NOW Covers Guardant Health’s Shield Blood Test for Colorectal Cancer Screening

THOMSON REUTERS
·
Jul 02

Guardant Health Rises on Unitedhealth Coverage Boost for Colorectal Cancer Kit

Reuters
·
Jul 02

Guardant Health is Maintained at Buy by BTIG

Dow Jones
·
Jul 02

Guardant Health price target raised to $190 from $160 at BTIG

TIPRANKS
·
Jul 02

Guardant rallies after UnitedHealth covers colorectal cancer test

TIPRANKS
·
Jul 01

Movement Alert|Guardant Health Rises 7.47% in Regular Trading, Bernstein Sees Revenue Upside From ADLT Pricing Qualification

Market Focus
·
Jul 01

Movement Alert|Guardant Health Pre-Market Rise 5.35%, Bernstein Sees Revenue Upside From ADLT Pricing Qualification

Market Focus
·
Jul 01

Guardant Health Co-ceo Amirali Talasaz Reports Disposal of Common Shares Worth $39.15 Million

Reuters
·
Jul 01

Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026

GlobeNewswire
·
Jul 01

Guardant Health is Maintained at Buy by Guggenheim

Dow Jones
·
Jun 29

Movement Alert|Guardant Health Rises 5.08% in Regular Trading, Multiple Catalysts Continue to Drive Momentum

Market Focus
·
Jun 27